Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention
- PMID: 33289114
- PMCID: PMC7852163
- DOI: 10.1002/clc.23520
Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention
Abstract
Recent studies and guidelines have indicated that lipoprotein(a) [Lp(a)]was an independent risk factor of arteriosclerotic cardiovascular disease (ASCVD). This study aimed to determine the relationship between serum Lp(a) levels and the risk of periprocedural myocardial injury following percutaneous coronary intervention (PCI) in coronary heartdisease (CHD) patients. This study enrolled 528 nonacute myocardial infarction (AMI) coronary heart disease (CHD) patients who successfully underwent PCI. Fasting serum lipids including Lp(a) were tested before PCI. High-sensitivity cardiac troponin I (hs-cTnI) was tested before PCI and 24 h after PCI. Univariate and multivariate logistic regression analyses were used to determine the relationship between preprocedural Lp(a) levels and postprocedural cTnI elevation from 1 × upper limit of normal (ULN) to 70 × ULN. As a continuous variable, multivariate analyses adjusting for conventional covariates and other serum lipids revealed that increased Lp(a) levels were independently associated with the risk of elevated postprocedural cTnI values above 1 × ULN (odds ratio [OR] per log-unit higher: 1.31, 95% confidence interval [CI]: 1.02-1.68, P = 0.033], 5 × ULN (OR: 1.25, 95%CI: 1.02-1.53, P = 0.032), 10 × ULN (OR: 1.48, 95%CI: 1.18-1.86, P = 0.001) and 15 × ULN (OR: 1.28, 95%CI: 1.01-1.61, P = 0.038). As a categorical variable, Lp(a) > 300 mg/L was an independent risk factor of postproceduralc TnI≥1 × ULN (OR 2.17, 95%CI 1.12-4.21, P = 0.022), ≥5 × ULN (OR 1.82, 95%CI 1.12-2.97, P = 0.017) and ≥10 × ULN (OR 2.17, 95%CI 1.33-3.54, P = 0.002). Therefore, it could be concluded that elevated preprocedural Lp(a) levels were associated with the risk of PCI-related myocardial injury in non-AMI CHD patients.
Keywords: high‐sensitivity cardiac troponin I; lipoprotein(a); percutaneous coronary intervention; periprocedural myocardial injury.
© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Conflict of interest statement
The authors have no conflicts of interests.
Figures



Similar articles
-
Preprocedural N-terminal pro-B-type natriuretic peptide as a useful marker for predicting periprocedural myocardial injury following percutaneous coronary intervention in diabetic patients without cardiac dysfunction.Scand J Clin Lab Invest. 2015 Nov;75(7):568-77. doi: 10.3109/00365513.2015.1060518. Epub 2015 Jul 30. Scand J Clin Lab Invest. 2015. PMID: 26203960
-
Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention.J Clin Lipidol. 2014 Jul-Aug;8(4):423-32. doi: 10.1016/j.jacl.2014.04.002. Epub 2014 Apr 15. J Clin Lipidol. 2014. PMID: 25110224
-
Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.J Am Heart Assoc. 2015 Jan 8;4(1):e001412. doi: 10.1161/JAHA.114.001412. J Am Heart Assoc. 2015. PMID: 25572484 Free PMC article.
-
Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention.Int J Cardiol Heart Vasc. 2020 May 26;28:100541. doi: 10.1016/j.ijcha.2020.100541. eCollection 2020 Jun. Int J Cardiol Heart Vasc. 2020. PMID: 32490148 Free PMC article.
-
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.J Am Coll Cardiol. 2013 Jul 16;62(3):242-251. doi: 10.1016/j.jacc.2013.04.043. Epub 2013 May 15. J Am Coll Cardiol. 2013. PMID: 23684676 Review.
Cited by
-
Relationship Between Preprocedural Lipid Levels and Periprocedural Myocardial Injury in Patients Undergoing Elective Percutaneous Coronary Intervention.Tex Heart Inst J. 2022 Nov 1;49(6):e207384. doi: 10.14503/THIJ-20-7384. Tex Heart Inst J. 2022. PMID: 36515930 Free PMC article.
-
Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial.BMJ Open. 2023 Jul 11;13(7):e072541. doi: 10.1136/bmjopen-2023-072541. BMJ Open. 2023. PMID: 37433737 Free PMC article.
-
Lipoprotein(a): Insights for the Practicing Clinician.J Clin Med. 2022 Jun 25;11(13):3673. doi: 10.3390/jcm11133673. J Clin Med. 2022. PMID: 35806958 Free PMC article. Review.
References
-
- Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692‐711. - PubMed
-
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111‐188. - PubMed
-
- Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala‐Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000;1488(3):189‐210. - PubMed
Grants and funding
- 201802010048/Guangzhou City Science and Technology Program for Industrial Technology Major Research Plan
- 2016A030313841/Natural Science Foundation of Guangdong Province
- 2020GZRPYQN18/the National Natural Science Foundation Cultivation Project of The Third Affiliated Hospital of Sun Yat-sen University
- 2016A030310203/the PhD Start-up Fund of Natural Science Foundation of Guangdong Province
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous